XML 57 R42.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Stock-based Compensation (Tables) | 12 Months Ended
--- | ---
Sep. 30, 2017 | Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] |  |
Summary of allocation of share-based compensation costs by plan |  | A summary of the expense related to stock-based compensation by award type is as follows for the periods presented:
|  | Fiscal Year Ended September 30,
(In millions) |  | 2017 |  | 2016 |  | 2015 |
Stock options expense |  | $ | 274 |  |  | $ | 534 |  |  | $ | 697 |  |
Restricted stock awards expense |  | 7,885 |  |  | 7,425 |  |  | 5,408 |  |
Before tax stock-based compensation expense |  | 8,159 |  |  | 7,959 |  |  | 6,105 |  |
Tax benefit |  | (2,917 | ) |  | (2,832 | ) |  | — |  | (a)
After tax stock-based compensation expense |  | $ | 5,242 |  |  | $ | 5,127 |  |  | $ | 6,105 |  |
(a) Tax impact is zero due to the existence of a valuation allowance on our deferred tax assets in prior year periods.
Schedule of assumptions for stock option activity | We used the following assumptions for stock options granted, which derived the weighted average fair value shown, for the period presented:
|  | Fiscal Year Ended September 30,
|  | 2017 |  | 2016 |  | 2015
Expected life of options |  | 5.4 years |  |  | 4.9 years |  |  | N/A(a)
Expected volatility |  | 50.10 | % |  | 46.49 | % |  | N/A
Expected dividends |  | — |  |  | — |  |  | N/A
Weighted average risk-free interest rate |  | 1.85 | % |  | 1.36 | % |  | N/A
Weighted average fair value |  | $ | 5.83 |  |  | $ | 4.03 |  |  | N/A
(a) N/A - Not applicable, as no stock options were granted during the period. |
Schedule of stock options and SSARs outstanding | Activity related to stock options for the periods presented is as follows:
| 2017 |  | 2016 |  | 2015
| Shares |  | Weighted- Average Exercise Price |  | Shares |  | Weighted- Average Exercise Price |  | Shares |  | Weighted- Average Exercise Price
Outstanding at beginning of period | 672,669 |  |  | $ | 16.49 |  |  | 643,907 |  |  | $ | 18.13 |  |  | 650,223 |  |  | $ | 18.12 |
Granted | 29,410 |  |  | 12.50 |  |  | 125,449 |  |  | 9.19 |  |  | — |  |  | — |
Exercised | (2,313 | ) |  | 10.80 |  |  | — |  |  | — |  |  | (1,209 | ) |  | 12.07 |
Expired | (84,976 | ) |  | 28.45 |  |  | (86,606 | ) |  | 19.70 |  |  | — |  |  | — |
Canceled | (480 | ) |  | 23.65 |  |  | — |  |  | — |  |  | — |  |  | — |
Forfeited | (20,557 | ) |  | 11.97 |  |  | (10,081 | ) |  | 10.98 |  |  | (5,107 | ) |  | 19.05 |
Outstanding at end of period | 593,753 |  |  | $ | 14.76 |  |  | 672,669 |  |  | $ | 16.49 |  |  | 643,907 |  |  | $ | 18.13 |
Exercisable at end of period | 476,606 |  |  | $ | 15.91 |  |  | 503,594 |  |  | $ | 17.76 |  |  | 491,029 |  |  | $ | 18.40 |
Vested or expected to vest in the future | 585,186 |  |  | $ | 14.83 |  |  | 672,669 |  |  | $ | 16.49 |  |  | 643,877 |  |  | $ | 18.13 |
Schedule of stock options and SSARS outstanding and exercisable | The following table summarizes information about stock options outstanding and exercisable as of September 30, 2017:
| Stock Options Outstanding |  | Stock Options Exercisable
Range of Exercise Price | Number Outstanding |  | Weighted Average Contractual Remaining Life (Years) |  | Weighted Average Exercise Price |  | Number Exercisable |  | Weighted Average Contractual Remaining Life (Years) |  | Weighted Average Exercise Price
$1 - $15 | 379,657 |  |  | 4.05 |  | $ | 11.63 |  |  | 262,610 |  |  | 2.87 |  | $ | 12.33 |
$16 - $20 | 157,129 |  |  | 3.99 |  | 19.08 |  |  | 157,029 |  |  | 3.99 |  | 19.08 |
$21- $30 | 56,967 |  |  | 0.12 |  | 23.65 |  |  | 56,967 |  |  | 0.12 |  | 23.65 |
$1- $30 | 593,753 |  |  | 3.66 |  | $ | 14.76 |  |  | 476,606 |  |  | 2.91 |  | $ | 15.91 |
Schedule of nonvested stock awards and performance shares | Activity relating to all restricted stock awards for the periods presented is as follows:
| Year Ended September 30, 2017
| Performance-Based |  | Time-Based |  | Total
| Shares |  | Weighted Average Grant Date Fair Value |  | Shares |  | Weighted Average Grant Date Fair Value |  | Shares |  | Weighted Average Grant Date Fair Value
Beginning of period | 448,693 |  |  | $ | 16.71 |  |  | 807,124 |  |  | $ | 17.52 |  |  | 1,255,817 |  |  | $ | 17.23 |
Granted | 263,696 |  |  | 13.60 |  |  | 271,855 |  |  | 12.50 |  |  | 535,551 |  |  | 13.04 |
Vested | — |  |  | — |  |  | (189,029 | ) |  | 15.52 |  |  | (189,029 | ) |  | 15.52 |
Forfeited | (43,623 | ) |  | 13.11 |  |  | (17,769 | ) |  | 14.08 |  |  | (61,392 | ) |  | 13.39 |
End of period | 668,766 |  |  | $ | 15.72 |  |  | 872,181 |  |  | $ | 16.47 |  |  | 1,540,947 |  |  | $ | 16.15 |
| Year Ended September 30, 2016
| Performance-Based |  | Time-Based |  | Total
| Shares |  | Weighted Average Grant Date Fair Value |  | Shares |  | Weighted Average Grant Date Fair Value |  | Shares |  | Weighted Average Grant Date Fair Value
Beginning of period | 252,022 |  |  | $ | 16.34 |  |  | 704,261 |  |  | $ | 18.97 |  |  | 956,283 |  |  | $ | 18.27 |
Granted | 231,624 |  |  | 15.43 |  |  | 259,819 |  |  | 14.04 |  |  | 491,443 |  |  | 14.69 |
Vested | — |  |  | — |  |  | (127,993 | ) |  | 18.58 |  |  | (127,993 | ) |  | 18.58 |
Forfeited | (34,953 | ) |  | 5.51 |  |  | (28,963 | ) |  | 16.78 |  |  | (63,916 | ) |  | 10.62 |
End of period | 448,693 |  |  | $ | 16.71 |  |  | 807,124 |  |  | $ | 17.52 |  |  | 1,255,817 |  |  | $ | 17.23 |
| Year Ended September 30, 2015
| Performance-Based |  | Time-Based |  | Total
| Shares |  | Weighted Average Grant Date Fair Value |  | Shares |  | Weighted Average Grant Date Fair Value |  | Shares |  | Weighted Average Grant Date Fair Value
Beginning of period | 166,413 |  |  | $ | 5.78 |  |  | 580,154 |  |  | $ | 18.62 |  |  | 746,567 |  |  | $ | 15.76 |
Granted | 201,157 |  |  | 19.03 |  |  | 209,035 |  |  | 19.00 |  |  | 410,192 |  |  | 19.01 |
Vested | — |  |  | — |  |  | (64,719 | ) |  | 15.96 |  |  | (64,719 | ) |  | 15.96 |
Forfeited | (115,548 | ) |  | 5.82 |  |  | (20,209 | ) |  | 18.95 |  |  | (135,757 | ) |  | 7.77 |
End of period | 252,022 |  |  | $ | 16.34 |  |  | 704,261 |  |  | $ | 18.97 |  |  | 956,283 |  |  | $ | 18.27 |

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details
Name: | us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the changes in outstanding nonvested shares. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(2) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details
Name: | us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock options and stock appreciation rights that were outstanding at the beginning and end of the year, exercisable at the end of the year, and the number of stock options and stock appreciation rights that were granted, exercised or converted, forfeited, and expired during the year. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationStockOptionsAndStockAppreciationRightsAwardActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details
Name: | us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration